Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Revenues | $1,418 | $18,658 | $11,677 | $69,575 |
| Operating expenses: | ||||
| Research and development | 17,598 | 13,322 | 36,836 | 32,189 |
| General and administrative | 7,601 | 6,622 | 18,294 | 16,050 |
| Total operating expenses | 25,199 | 19,944 | 55,130 | 48,239 |
| Income (loss) from operations | (23,781) | (1,286) | (43,453) | 21,336 |
| Interest income | 3,157 | 1,178 | 4,647 | 2,133 |
| Other income | 18 | 17 | 11 | 28 |
Item 1. Condensed Financial Statements (Unaudited)
FAQ
- What is CytomX Therapeutics's G&A?
- CytomX Therapeutics (CTMX) reported G&A of $7.6M in Q2 2026.
- How has CytomX Therapeutics's G&A changed year-over-year?
- CytomX Therapeutics's G&A increased by 14.8% year-over-year, from $6.62M to $7.6M.
- What is the long-term trend for CytomX Therapeutics's G&A?
- Over 4 years (2021 to 2025), CytomX Therapeutics's G&A has grown at a -6.6% compound annual growth rate (CAGR), from $39.16M to $29.84M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about CytomX Therapeutics's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude